In an effort to curb abuse of over-the-counter cold and cough medications by minors, Washington Gov. Jay Inslee on Friday signed legislation — House Bill 2163 — that places an age restriction on the purchase of dextromethorphan.
Reps. Bill Johnson, R-Ohio, and Bruce Braley, D-Iowa, last week introduced bipartisan legislation — the Preventing Abuse of Cough Medicine Treatment Act — that would help combat the abuse of dextromethorphan by placing an age restriction on its purchase.
The Consumer Healthcare Products Association on Friday pledged its support behind the introduction of legislation by Rep. Paul Harris, R-Wash., that would prohibit pharmacies or retail distributors from selling over-the-counter cough medicines containing dextromethorphan to those younger than 18 years without a prescription.
Abuse of the cough ingredient dextromethorphan among high school seniors is down, according to this year’s Monitoring the Future survey, which measures drug use and attitudes among the nation’s eighth-, 10th- and 12th-graders.
Sens. Bob Casey, D-Pa., and Lisa Murkowski, R-Ark., on Friday introduced the Preventing Abuse of Cough Treatments Act of 2013, which would require retailers to restrict the sale of dextromethorphan-containing products to adults.
Mylan on Friday announced that its partner Famy Care has received final approval from the Food and Drug Administration for its abbreviated new drug application for levonorgestrel and ethinyl estradiol Tablets USP in the 0.15mg/0.03mg strength.
The National Institute on Drug Abuse last week released the 2012 Monitoring the Future survey, finding that 5.6% of high school seniors, 3% of eighth graders and 4.7% of tenth graders abused over-the-counter cough and cold medicines containing dextromethorphan, bringing the overall average to under 5%.
In 2011 and 2012, the steady surge of blockbuster pharmaceuticals falling off the patent cliff became a stampede. An astonishing number of big-selling drugs that had established and sustained branded drug makers’ profits for years fell victim to the expiration of their patent lives and market exclusivity, roiling the pharmaceutical marketplace and redefining the pricing model for many of the most widely prescribed classes of medicines.